



# Toxicological Profile for Hexachlorocyclohexane (HCH)

March 2024



U.S. Department of Health and Human Services  
Agency for Toxic Substances and Disease Registry

CS274127-A

## **DISCLAIMER**

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

## FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute-, intermediate-, and chronic-duration exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry  
Centers for Disease Control and Prevention

## VERSION HISTORY

Date	Description
March 2024	Final toxicological profile released
January 2023	Draft for public comment toxicological profile released
August 2005	Final toxicological profile released
July 1999	Final toxicological profile released
May 1994	Final toxicological profile released
December 1989	Final toxicological profile released

## CONTRIBUTORS & REVIEWERS

### CHEMICAL MANAGER TEAM

Malcolm Williams, D.V.M., Ph.D. (Lead)  
Melanie Buser, M.P.H.  
Gaston Casillas, Ph.D.

Heather Carlson-Lynch, M.S., D.A.B.T.  
Claire Heit, Ph.D.  
Julie Melia, Ph.D., D.A.B.T.  
Jennifer Rhoades, B.A.  
Savannah Sierco, M.S.

ATSDR, Office of Innovation and Analytics,  
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

### REVIEWERS

#### Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

#### Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

### PEER REVIEWERS

1. Lisa Kamendulis, Ph.D.; Department of Environmental and Occupational Health; Indiana University Bloomington; Bloomington, Indiana
2. Russell C. Cattley, VMD, Ph.D., Dipl. ACVP, Fellow IATP; Tyler & Frances Young Professor of Pathology; Greene Hall; College of Veterinary Medicine; Auburn University, Alabama
3. Stephen M. Roberts, Ph.D.; Director, Center for Environmental & Human Toxicology; Professor, College of Veterinary Medicine; College of Medicine, and College of Public Health and Health Professions; University of Florida; Gainesville, Florida

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

## CONTENTS

DISCLAIMER .....	ii
FOREWORD .....	iii
VERSION HISTORY .....	iv
CONTRIBUTORS & REVIEWERS .....	v
CONTENTS.....	vi
LIST OF FIGURES .....	viii
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH .....	1
1.1 OVERVIEW AND U.S. EXPOSURES .....	1
1.2 SUMMARY OF HEALTH EFFECTS.....	1
1.3 MINIMAL RISK LEVELS (MRLs) .....	11
CHAPTER 2. HEALTH EFFECTS.....	19
2.1 INTRODUCTION.....	19
2.2 DEATH .....	99
2.3 BODY WEIGHT.....	102
2.4 RESPIRATORY.....	105
2.5 CARDIOVASCULAR.....	107
2.6 GASTROINTESTINAL.....	109
2.7 HEMATOLOGICAL .....	110
2.8 MUSCULOSKELETAL .....	113
2.9 HEPATIC.....	114
2.10 RENAL .....	123
2.11 DERMAL.....	130
2.12 OCULAR .....	131
2.13 ENDOCRINE.....	131
2.14 IMMUNOLOGICAL .....	136
2.15 NEUROLOGICAL.....	140
2.16 REPRODUCTIVE .....	150
2.17 DEVELOPMENTAL.....	163
2.18 OTHER NONCANCER.....	190
2.19 CANCER.....	195
2.20 GENOTOXICITY .....	202
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS .....	209
3.1 TOXICOKINETICS.....	209
3.1.1 Absorption.....	210
3.1.2 Distribution .....	212
3.1.3 Metabolism.....	215
3.1.4 Excretion .....	217
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .....	219
3.1.6 Animal-to-Human Extrapolations .....	221
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE .....	222
3.3 BIOMARKERS OF EXPOSURE AND EFFECT .....	225

3.3.1	Biomarkers of Exposure.....	226
3.3.2	Biomarkers of Effect.....	228
3.4	INTERACTIONS WITH OTHER CHEMICALS.....	228
CHAPTER 4.	CHEMICAL AND PHYSICAL INFORMATION.....	232
4.1	CHEMICAL IDENTITY.....	232
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	233
CHAPTER 5.	POTENTIAL FOR HUMAN EXPOSURE.....	236
5.1	OVERVIEW.....	236
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	237
5.2.1	Production.....	237
5.2.2	Import/Export.....	238
5.2.3	Use.....	239
5.2.4	Disposal.....	240
5.3	RELEASES TO THE ENVIRONMENT.....	241
5.3.1	Air.....	241
5.3.2	Water.....	243
5.3.3	Soil.....	245
5.4	ENVIRONMENTAL FATE.....	245
5.4.1	Transport and Partitioning.....	245
5.4.2	Transformation and Degradation.....	251
5.5	LEVELS IN THE ENVIRONMENT.....	256
5.5.1	Air.....	259
5.5.2	Water.....	259
5.5.3	Sediment and Soil.....	270
5.5.4	Other Media.....	270
5.6	GENERAL POPULATION EXPOSURE.....	281
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	289
CHAPTER 6.	ADEQUACY OF THE DATABASE.....	291
6.1	EXISTING INFORMATION ON HEALTH EFFECTS.....	291
6.2	IDENTIFICATION OF DATA NEEDS.....	291
6.3	ONGOING STUDIES.....	302
CHAPTER 7.	REGULATIONS AND GUIDELINES.....	303
CHAPTER 8.	REFERENCES.....	306
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR HCH.....	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR HCH.....	C-1
APPENDIX D.	USER'S GUIDE.....	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	E-1
APPENDIX F.	GLOSSARY.....	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

## LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to $\gamma$ -Hexachlorocyclohexane .....	3
1-2. Health Effects Found in Animals Following Oral Exposure to $\alpha$ -Hexachlorocyclohexane .....	3
1-3. Health Effects Found in Animals Following Oral Exposure to $\beta$ -Hexachlorocyclohexane .....	4
1-4. Health Effects Found in Animals Following Oral Exposure to $\gamma$ -Hexachlorocyclohexane .....	5
1-5. Health Effects Found in Animals Following Oral Exposure to Technical Hexachlorocyclohexane.....	6
1-6. Summary of Sensitive Targets of $\alpha$ -Hexachlorocyclohexane ( $\alpha$ -HCH) – Oral .....	12
1-7. Summary of Sensitive Targets of $\beta$ -Hexachlorocyclohexane ( $\beta$ -HCH) – Oral .....	13
1-8. Summary of Sensitive Targets of $\gamma$ -Hexachlorocyclohexane ( $\gamma$ -HCH) – Inhalation.....	14
1-9. Summary of Sensitive Targets of $\gamma$ -Hexachlorocyclohexane ( $\gamma$ -HCH) – Oral.....	15
1-10. Summary of Sensitive Targets of Technical-Hexachlorocyclohexane (technical-HCH) – Oral .....	16
2-1. Overview of the Number of Studies Examining $\alpha$ -Hexachlorocyclohexane ( $\alpha$ -HCH) Health Effects.....	23
2-2. Overview of the Number of Studies Examining $\beta$ -Hexachlorocyclohexane ( $\beta$ -HCH) Health Effects.....	24
2-3. Overview of the Number of Studies Examining $\gamma$ -Hexachlorocyclohexane ( $\gamma$ -HCH) Health Effects.....	25
2-4. Overview of the Number of Studies Examining $\delta$ -Hexachlorocyclohexane ( $\delta$ -HCH) and Unspecified Hexachlorocyclohexanes Health Effects.....	26
2-5. Levels of Significant Exposure to $\gamma$ -Hexachlorocyclohexane (Lindane) – Inhalation .....	29
2-6. Levels of Significant Exposure to $\alpha$ -Hexachlorocyclohexane – Oral.....	36
2-7. Levels of Significant Exposure to $\beta$ -Hexachlorocyclohexane – Oral.....	46
2-8. Levels of Significant Exposure to $\gamma$ -Hexachlorocyclohexane – Oral .....	74
2-9. Levels of Significant Exposure to $\delta$ - and Technical Hexachlorocyclohexane (HCH) – Oral .....	90
3-1. The Proposed Metabolism of Hexachlorocyclohexane .....	216
5-1. Number of NPL Sites with Hexachlorocyclohexane Contamination .....	236
6-1. Summary of Existing Health Effects Studies on $\alpha$ -Hexachlorocyclohexane by Route and Endpoint .....	292



6-2. Summary of Existing Health Effects Studies on  $\beta$ -Hexachlorocyclohexane by Route and Endpoint ..... 293

6-3. Summary of Existing Health Effects Studies on  $\gamma$ -Hexachlorocyclohexane by Route and Endpoint ..... 294

6-4. Summary of Existing Health Effects Studies on  $\delta$ -Hexachlorocyclohexane and Unspecified Hexachlorocyclohexanes by Route and Endpoint ..... 295

## LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for $\alpha$ -Hexachlorocyclohexane .....	17
1-2. Minimal Risk Levels (MRLs) for $\beta$ -Hexachlorocyclohexane .....	17
1-3. Minimal Risk Levels (MRLs) for $\gamma$ -Hexachlorocyclohexane .....	18
2-1. Levels of Significant Exposure to $\gamma$ -Hexachlorocyclohexane – Inhalation.....	27
2-2. Levels of Significant Exposure to $\alpha$ -Hexachlorocyclohexane – Oral.....	31
2-3. Levels of Significant Exposure to $\beta$ -Hexachlorocyclohexane – Oral.....	40
2-4. Levels of Significant Exposure to $\gamma$ -Hexachlorocyclohexane – Oral.....	50
2-5. Levels of Significant Exposure to $\delta$ - and Technical Hexachlorocyclohexane – Oral .....	81
2-6. Levels of Significant Exposure to $\gamma$ -Hexachlorocyclohexane – Dermal .....	94
2-7. Levels of Significant Exposure to Technical Hexachlorocyclohexane – Dermal .....	96
2-8. Summary of Epidemiological Studies of $\beta$ -Hexachlorocyclohexane ( $\beta$ -HCH) Exposure and Body Weight Effects .....	103
2-9. Summary of Epidemiological Studies of $\beta$ -Hexachlorocyclohexane Exposure and Cardiovascular Effects.....	107
2-10. Summary of Epidemiological Studies of $\beta$ -Hexachlorocyclohexane Exposure and Hepatic Effects.....	114
2-11. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Renal Effects .....	124
2-12. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Endocrine Effects .....	132
2-13. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Immune Effects .....	137
2-14. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Neurological Effects.....	142
2-15. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Reproductive Effects .....	151
2-16. Summary of Epidemiological Studies of $\alpha$ -Hexachlorocyclohexane (HCH) Exposure and Developmental Effects .....	164
2-17. Summary of Epidemiological Studies of $\beta$ -Hexachlorocyclohexane Exposure and Developmental Effects .....	167

2-18. Summary of Epidemiological Studies of $\gamma$ -Hexachlorocyclohexane Exposure and Developmental Effects .....	178
2-19. Summary of Epidemiological Studies of $\delta$ -HCH and Total HCH Exposure and Developmental Effects .....	189
2-20. Summary of Epidemiological Studies of Hexachlorocyclohexane (HCH) Exposure and Other Noncancer Effects .....	191
2-21. Summary of Epidemiological Studies Evaluating Possible Associations between Hexachlorocyclohexane Exposure and Risk of Selected Cancer Types.....	195
2-22. Genotoxicity of Hexachlorocyclohexane Isomers <i>In Vivo</i> .....	202
2-23. Genotoxicity of Hexachlorocyclohexane Isomers <i>In Vitro</i> .....	203
4-1. Chemical Identity of Hexachlorocyclohexane Isomers .....	232
4-2. Physical and Chemical Properties of Hexachlorocyclohexane Isomers .....	234
5-1. Facilities that Produce, Process, or Use $\gamma$ -Hexachlorocyclohexane .....	237
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Hexachlorobenzenes .....	242
5-3. $\gamma$ -HCH Emissions as Reported by the 2017 National Emission Inventory .....	243
5-4. Results of Experimental Bioaccumulation Studies with $\gamma$ -Hexachlorocyclohexane .....	249
5-5. Lowest Limit of Detection Based on Standards .....	256
5-6. Summary of Ambient Environmental Levels of HCH .....	257
5-7. Hexachlorocyclohexanes Levels in Water, Soil, and Air of National Priorities List (NPL) Sites .....	258
5-8. Outdoor Air Monitoring Data for Hexachlorocyclohexanes (HCHs).....	260
5-9. Water Monitoring Data for Hexachlorocyclohexanes (HCHs) .....	264
5-10. Soil and Sediment Monitoring Data for Hexachlorocyclohexanes (HCHs).....	271
5-11. Organism Monitoring Data for Hexachlorocyclohexanes (HCHs) .....	275
5-12. Geometric Mean of the Serum Concentration (ng/g) of $\beta$ -Hexachlorocyclohexane ( $\beta$ -HCH) (2015–2016) and $\gamma$ -Hexachlorocyclohexane ( $\gamma$ -HCH) (2011–2012) in the U.S. Population .....	285
7-1. Regulations and Guidelines Applicable to Hexachlorocyclohexane (HCH).....	303